These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28800127)

  • 1. Mnt modulates Myc-driven lymphomagenesis.
    Campbell KJ; Vandenberg CJ; Anstee NS; Hurlin PJ; Cory S
    Cell Death Differ; 2017 Dec; 24(12):2117-2126. PubMed ID: 28800127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
    Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
    Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
    Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
    Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes.
    Yang H; Li TW; Ko KS; Xia M; Lu SC
    Hepatology; 2009 Mar; 49(3):860-70. PubMed ID: 19086036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis.
    Link JM; Hurlin PJ
    Biochim Biophys Acta; 2015 May; 1849(5):554-62. PubMed ID: 24731854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromatin dynamics at the hTERT promoter during transcriptional activation and repression by c-Myc and Mnt in Xenopus leavis oocytes.
    Wahlström T; Belikov S; Arsenian Henriksson M
    Exp Cell Res; 2013 Dec; 319(20):3160-9. PubMed ID: 23860446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Of Myc and Mnt.
    Hooker CW; Hurlin PJ
    J Cell Sci; 2006 Jan; 119(Pt 2):208-16. PubMed ID: 16410546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FoxO3 suppresses Myc-driven lymphomagenesis.
    Vandenberg CJ; Motoyama N; Cory S
    Cell Death Dis; 2016 Jan; 6(1):e2046. PubMed ID: 26764572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mnt-Max to Myc-Max complex switching regulates cell cycle entry.
    Walker W; Zhou ZQ; Ota S; Wynshaw-Boris A; Hurlin PJ
    J Cell Biol; 2005 May; 169(3):405-13. PubMed ID: 15866886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells.
    Lafita-Navarro MC; Liaño-Pons J; Quintanilla A; Varela I; Blanco R; Ourique F; Bretones G; Aresti J; Molina E; Carroll P; Hurlin P; Romero OA; Sanchez-Céspedes M; Eisenman RN; Delgado MD; León J
    J Biol Chem; 2020 Feb; 295(7):2001-2017. PubMed ID: 31919096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.
    Hurlin PJ; Quéva C; Eisenman RN
    Genes Dev; 1997 Jan; 11(1):44-58. PubMed ID: 9000049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC needs MNT.
    Link JM; Hurlin PJ
    Cell Cycle; 2013 Feb; 12(3):385-6. PubMed ID: 23324353
    [No Abstract]   [Full Text] [Related]  

  • 13. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome.
    Toyo-oka K; Hirotsune S; Gambello MJ; Zhou ZQ; Olson L; Rosenfeld MG; Eisenman R; Hurlin P; Wynshaw-Boris A
    Hum Mol Genet; 2004 May; 13(10):1057-67. PubMed ID: 15028671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells.
    Dezfouli S; Bakke A; Huang J; Wynshaw-Boris A; Hurlin PJ
    Mol Cell Biol; 2006 Mar; 26(6):2080-92. PubMed ID: 16507988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mnt transcriptional repressor is functionally regulated during cell cycle progression.
    Popov N; Wahlström T; Hurlin PJ; Henriksson M
    Oncogene; 2005 Dec; 24(56):8326-37. PubMed ID: 16103876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis.
    Link JM; Ota S; Zhou ZQ; Daniel CJ; Sears RC; Hurlin PJ
    Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19685-90. PubMed ID: 23150551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.
    Zhang Z; Sun H; Dai H; Walsh RM; Imakura M; Schelter J; Burchard J; Dai X; Chang AN; Diaz RL; Marszalek JR; Bartz SR; Carleton M; Cleary MA; Linsley PS; Grandori C
    Cell Cycle; 2009 Sep; 8(17):2756-68. PubMed ID: 19652553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mnt: a novel Max-interacting protein and Myc antagonist.
    Hurlin PJ; Qúeva C; Eisenman RN
    Curr Top Microbiol Immunol; 1997; 224():115-21. PubMed ID: 9308234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation.
    Nilsson JA; Maclean KH; Keller UB; Pendeville H; Baudino TA; Cleveland JL
    Mol Cell Biol; 2004 Feb; 24(4):1560-9. PubMed ID: 14749372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis.
    Diolaiti D; McFerrin L; Carroll PA; Eisenman RN
    Biochim Biophys Acta; 2015 May; 1849(5):484-500. PubMed ID: 24857747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.